Not available
Quote | Affimed N.V. (NASDAQ:AFMD)
Last: | $4.93 |
---|---|
Change Percent: | 1.02% |
Open: | $4.88 |
Close: | $4.88 |
High: | $4.99 |
Low: | $4.56 |
Volume: | 69,235 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Affimed N.V. (NASDAQ:AFMD)
The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been accepted for poster presentation MANNHEIM, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- Affimed N....
2024-03-28 12:04:42 ET Affimed N.V. (AFMD) Q4 2023 Earnings Conference Call March 28, 2024 8:30 AM ET Company Participants Alexander Fudukidis – Head-Investor Relations Andreas Harstrick – Chief Medical Officer and Interim Acting Chief Executive Officer...
Message Board Posts | Affimed N.V. (NASDAQ:AFMD)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $AFMD Hod.9269 F149.34M ML.66 off LL.55 RH10+24 +5.53% 676,459 .870900 149,339,335 +5.53% | znewcar1 | investorshangout | 04/25/2023 5:06:53 PM |
whytestocks: $AFMD News Article - Affimed Shares Preclinical Data on AFM13's Mechanism of Action Dem | whytestocks | investorshangout | 04/17/2023 8:15:49 PM |
NK is a slow cooker looking at MDACC | NY1972 | investorshub | 04/12/2023 1:38:58 AM |
I am worried about the potential for on-target, | jondoeuk | investorshub | 04/11/2023 7:53:21 PM |
CD123 is found in CSCs, which are not | NY1972 | investorshub | 04/10/2023 9:07:19 PM |
News, Short Squeeze, Breakout and More Instantly...
Affimed N.V. Company Name:
AFMD Stock Symbol:
NASDAQ Market:
The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been accepted for poster presentation MANNHEIM, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- Affimed N....
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...
AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR -wildtype cohort: one complete response (CR), three partial responses (PR), and seven stable disease patients in the 15 heavily p...